hotspot -WSS

hotspot

author：hotspot 2025-09-06 08:24:51 - browse：35

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Biotech startup Celsius cuts 75% of staff ahead of first trial start

explore

WSS

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Elevance, SCAN deals highlight health insurer acquisition scrutiny

How to ethically and practically extend health care to all

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Chris Christie meets with Zelenskyy during Ukraine trip

leisure time

hotspot

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Congress may force more Covid

New air purifier tech could be key to improving indoor air quality

A controversial new treatment promises to make little people taller

Affirmative action in medical school literally saved lives

When waiting feels immoral: Empathy in the emergency department

Duchenne breakthrough therapy leaves behind pioneering families

It costs an awful lot of money to give away a kidney

Hepatitis C has a cure — but many Americans still lack access to it

When waiting feels immoral: Empathy in the emergency department

hotspot

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Researchers tackle phage therapy hurdles for wider adoption

Flagship Pioneering startup Sonata Therapeutics lays off 21

In 'major milestone,' FDA approves first cell therapy for solid tumors

Obamacare plans could cover weight loss drugs

It costs an awful lot of money to give away a kidney

focus

hotspot

explore

leisure time